JP2015505303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505303A5 JP2015505303A5 JP2014546471A JP2014546471A JP2015505303A5 JP 2015505303 A5 JP2015505303 A5 JP 2015505303A5 JP 2014546471 A JP2014546471 A JP 2014546471A JP 2014546471 A JP2014546471 A JP 2014546471A JP 2015505303 A5 JP2015505303 A5 JP 2015505303A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- pharmaceutical composition
- lipocalin mutein
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570018P | 2011-12-13 | 2011-12-13 | |
| US61/570,018 | 2011-12-13 | ||
| PCT/EP2012/075146 WO2013087660A1 (en) | 2011-12-13 | 2012-12-12 | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067615A Division JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505303A JP2015505303A (ja) | 2015-02-19 |
| JP2015505303A5 true JP2015505303A5 (https=) | 2016-02-04 |
| JP6163162B2 JP6163162B2 (ja) | 2017-07-12 |
Family
ID=47552959
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546471A Expired - Fee Related JP6163162B2 (ja) | 2011-12-13 | 2012-12-12 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2017067615A Expired - Fee Related JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2019062186A Expired - Fee Related JP6889201B2 (ja) | 2011-12-13 | 2019-03-28 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2020092168A Pending JP2020164532A (ja) | 2011-12-13 | 2020-05-27 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2022049676A Active JP7441589B2 (ja) | 2011-12-13 | 2022-03-25 | Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067615A Expired - Fee Related JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2019062186A Expired - Fee Related JP6889201B2 (ja) | 2011-12-13 | 2019-03-28 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2020092168A Pending JP2020164532A (ja) | 2011-12-13 | 2020-05-27 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2022049676A Active JP7441589B2 (ja) | 2011-12-13 | 2022-03-25 | Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9572863B2 (https=) |
| EP (3) | EP3842058B1 (https=) |
| JP (5) | JP6163162B2 (https=) |
| CN (2) | CN103998053B9 (https=) |
| AU (1) | AU2012350660B2 (https=) |
| CA (1) | CA2858962C (https=) |
| DK (2) | DK2790719T3 (https=) |
| ES (2) | ES2710384T3 (https=) |
| HU (2) | HUE054342T2 (https=) |
| PL (2) | PL3453400T3 (https=) |
| SG (2) | SG11201402992SA (https=) |
| TR (1) | TR201901826T4 (https=) |
| WO (1) | WO2013087660A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| EP3842058B1 (en) | 2011-12-13 | 2023-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| WO2015177175A2 (en) | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| WO2017009456A1 (en) | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| CN113372446A (zh) * | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| CA3050194A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| JP7657548B2 (ja) * | 2017-04-21 | 2025-04-07 | エランコ・ユーエス・インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| US20220193191A1 (en) * | 2019-03-29 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| KR20230121785A (ko) | 2020-12-18 | 2023-08-21 | 아스트라제네카 에이비이 | 천식 치료용 리포칼린 뮤테인 건조 분말 제형 |
| CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| DK1087778T3 (da) | 1998-06-08 | 2005-12-19 | Hoffmann La Roche | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| US8598317B2 (en) | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| EP2046820B1 (en) * | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| KR20100047866A (ko) * | 2007-07-11 | 2010-05-10 | 애로반스, 인코포레이티드 | 약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법 |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| EP3842058B1 (en) | 2011-12-13 | 2023-08-23 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
-
2012
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en not_active Ceased
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en not_active Ceased
- 2012-12-12 US US14/364,449 patent/US9572863B2/en not_active Expired - Fee Related
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja not_active Expired - Fee Related
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh not_active Expired - Fee Related
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh not_active Expired - Fee Related
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja not_active Expired - Fee Related
- 2019-07-16 US US16/513,636 patent/US10857202B2/en not_active Expired - Fee Related
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505303A5 (https=) | ||
| JP6889201B2 (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| JP7169693B2 (ja) | 呼吸器疾患の治療 | |
| CN108778316B (zh) | 糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病 | |
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| EP3551187B1 (en) | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol | |
| RU2015144185A (ru) | Лечение заболеваний, опосредованных тh2, путем ингибирования бромодоменов | |
| Cao et al. | M3 muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice | |
| Ohga et al. | The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo | |
| JP2017509633A5 (https=) | ||
| RU2013157398A (ru) | Композиция | |
| JP2017528454A5 (https=) | ||
| KR102875179B1 (ko) | 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물 | |
| CN115697301A (zh) | 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法 | |
| CN101883566B (zh) | 用于治疗或预防涉及组胺h4受体的病症的美喹他嗪 | |
| Baradia et al. | Inhalation therapy to treat pulmonary arterial hypertension | |
| Syabbalo | The role of airway remodeling in the pathogenesis and treatment of chronic obstructive pulmonary disease | |
| WO2020247136A2 (en) | USE OF R-ENANTIOMER β2-AGONISTS FOR PREVENT AND TREATMENT OF PULMONARY INFLAMMATION AND INFLAMMATORY REMODELING FOR REDUCED ADVERSE EFFECTS | |
| CN115381843A (zh) | L-岩藻糖在制备呼吸系统疾病治疗药物中的用途 | |
| Nishihara et al. | 155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis | |
| Park et al. | 153 Effect of Simvastatin on Transforming Growth Factor BETA-1-Induced Myofibroblast Differentiation and Collagen Production in Nasal Polyp-Derived Fibroblasts |